Shots:

• Mycenax to get $5M upfront and will get $16.5M as total deal value in four installments. Richter to get exclusive WW rights to develop- manufacture and commercialize biosimilar tocilizumab
• The focus of the agreement is to bolster its rheumatology portfolio with addition of Mycenax’s candidate. The biosimilar tocilizumab assets comprise the cell lines- intellectual property (IP) rights- technology know-how also the data generated by Mycenax
• Tocilizumab is an investigational product formulated as subcutaneous and intravenous formulations targeted for RA with expected  commercialization in EU- Canada- Australia and Japan in 2025 and is approved for paediatric juvenile idiopathic arthritis- systemic juvenile idiopathic arthritis- giant cell arteritis and CAR-T cell-induced cytokine release syndrome

Click here to read full press release/ article | Ref: Gedeon Richter | Image: Behance